WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 2'2601 Infant (under 12 months) mortality rate: 382
GDP / capita (US$): 2'4611 Child (under 5 years) mortality rate: 472

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 101  99  98  96  95  83  71  55 
Births
Surviving infants
Pop. less than 5 years 11  11  11  11  11  12  11 
Pop. less than 15 years 33  33  33  33  33  33  29  22 
Female 15-49 years 27  27  26  26  25  21  17  13 

Number of reported case

(Click for retrospective incidence data for Kiribati)
Diphtheria
Japanese encephalitis
Measles 30  170 
Mumps
Pertussis 830  161 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Kiribati)
Vaccine year result method % card seen                                                
BCG          95  86  87  76  83  80  93  66 
DTP1          94  99*  90  90  97  95 
DTP3          94  99  91  86  82  90  97  43 
HepB_BD          82  66  63  52  59  80 
HepB3          94  95  91  86  83  90  73 
Hib3          94  95  91  86  83 
JapEnc         
MCV          91  90  89  82  72  80  75 
MCV2          61  21  35 
PCV1         
PCV3         
Pol3          92  95  95  84  74  90  97  10 
Rota1         
Rota_last         
Rubella1          91  90  72 
TT2plus          100  83  79  42  50  54 
PAB         
VAD1          100  58  77 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Kiribati)
BCG 95  86  87  76  83  80  93  66 
DTP1 94  99  97  90  97  95  98  68 
DTP3 94  99  91  86  82  90  97  43 
HepB3 94  95  91  86  83  90  73 
Hib3 94  95  91  86  83 
MCV 91  90  89  82  72  80  75 
PCV3
Pol3 92  95  95  84  74  90  97  10 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwP 6 years; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HPV 9-13 years (x3); No
HepB birth; Yes
MR 12 months; 6 years; Yes
OPV 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes From May 2013
Rotavirus From 2014
TT 13 years; Yes
VitaminA 6-12 months; 13 months to 6 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2017  2008-2012  2008-2012  2008-2012      2007-2011 
Nº of districts with microplans that include activities to raise immunization coverage number     NA 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR No  Yes  Yes         

System performance

Total number of districts in country number 24 
Nº districts with DTP3 coverage >=80% number 11   
% of districts with DTP3 coverage >=80% From 0 to 100% 100  83  83  46    100  33 
Nº districts with measles (MCV1) coverage >=95% number      
% of districts with MCV1 coverage >=95% From 0 to 100% 50  17  17  33       

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  No   
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100%   111    100  100  100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.